검색어: phospholipidosis (영어 - 몰타어)

temsirolimus has been associated with phospholipidosis in rats.
temsirolimus kien assoċjat ma’ fosfolipidosi fil-firien.

the significance of phospholipidosis in humans is unknown.
is-sinifikat ta’ fosfolipidosi fil-bniedem mhux magħruf.

amphiphilic agents temsirolimus has been associated with phospholipidosis in rats.
sustanzi amfifiliċi temsirolimus kien assoċjat ma ’ fosfolipidosi fil- firien.

phospholipidosis occurs at acceptable human to animal safety margins and was reversible.
fosfolipidożi sseħħ f’marġini ta’ sigurtà aċċettabbli għall-bniedem u l- annimal u kienet riversibbli.

phospholipidosis in pulmonary macrophages due to accumulation of memantine in lysosomes was observed in rodents.
fosfolipidożi f’makrofaġi fil-pulmun minħabba l-akkumulazzjoni ta’ memantine f’lisożomi ġiet osservata f’annimali ġerriema.

phospholipidosis (intracellular phospholipid accumulation) affecting a number of organs and tissues me
pr

pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats.
fosfolipidożi pulmonari li tirriżulta f’dilatazzjoni u ostruzzjoni ta’ alvejoli dehret fl-istudju ta’ sentejn fil-firien.

phospholipidosis has not been observed in mice or monkeys treated with temsirolimus, nor has it been documented in patients treated with temsirolimus.
il-fosfolipidosi ma kinitx osservata fil-ġrieden jew fix-xadini li kienu kkurati b’temsirolimus, u lanqas ma kienet dokumentata f’pazjenti kkurati b’temsirolimus.

phospholipidosis (foamy macrophages) has been observed with the administration of netupitant after repeated administration in rats and dogs.
fosfolipidosi (makrofaġi bir- ragħwa) ġiet osservata bl-għoti ta’ netupitant wara l-għoti ripetut fil-firien u l-klieb.

neuronal phospholipidosis occurred in dogs dosed for ≥ 3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
fosfolipidożi newronali seħħet fi klieb li ngħataw dożi għal ≥ 3 xhur b’ esponimenti aktar baxxi minn dawk li jinkisbu b’ dożi terapewtiċi fil- bnedmin.

of all species, pigment-laden and/or foamy macrophages were also seen in various tissues, consistent with phospholipidosis.
fl-mps ta’ kull speċi, ġew osservati pigments u/jew makrofaġi bil-fowm f’tessuti diversi, konsistenti ma’ fosfolipidosi.

in chronic toxicity studies, slight and reversible phospholipidosis (accumulation of foamy macrophages) was observed in mesenteric lymph nodes mainly in the rat.
f’studji kroniċi ta’ tossiċità, ġiet osservata fosfolipidożi ( ġabra ta’ makrofaġi li jkunu mimlija bil- lipidi ragħwin) fin-nodi limfatiċi mesenteriċi, l-iżjed fil-firien.

although phospholipidosis has not been shown to be a risk for patients administered temsirolimus, it is possible that combined administration of temsirolimus with other amphiphilic agents such as amiodarone or statins could result in an increased risk of amphiphilic pulmonary toxicity.
għalkemm ma ntweriex li l-fosfolipidosi hi ta’ riskju għal pazjenti li jingħataw temsirolimus, hu possibbli li l-għoti flimkien ta’ temsirolimus ma’ sustanzi amfifiliċi oħrajn bħal amiodarone jew statins, jista’ jirriżulta f’żieda fir-riskju ta’ tossiċità pulmonari amfifilika.

alveolar foamy macrophages (confirmed phospholipidosis) were seen in the lungs of rats, but not in monkeys, and the lymph nodes of rats and monkeys had macrophage aggregates.
kien hemm makrofaġi alveolari bir-ragħwa (fosfolipidożi kkonfermata) fil-pulmuni tal- firien, imma mhux f’tax-xadini, u n-nodi linfatiċi tal-firien u x-xadini kellhom makrofaġi miġmugħa.

phospholipidosis was seen mainly in the lungs in rodents (at exposures similar to humans) and monkeys (at exposures greater than 12 fold higher than human).
Ġiet osservata fosfolipidożi prinċipalment fil-pulmuni fir-rodituri b’esponimenti simili għal dak tal-bniedem) u x-xadini (b’esponimenti aktar minn 12.8 darba ogħla minn tal-bniedem).

adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: pancreatic islet cell vacuolation, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and calluses, hepatic haematopoiesis, and pulmonary phospholipidosis.
ma dehrux effetti mhux mixtieqa waqt studji kliniċi, iżda dehru f’annimali li ġew esposti għal doża daqs dik klinika u jista’ jkollhom rilevanza għall-użu kliniku, kif spjegat: vakwolazzjoni taċ-ċelluli tal- frixa, tħassir tat-tubi testikolari, ulċerazzjoni gastrointestinali, ksur tal-għadam u kallijiet, ematopojesi epatika, u fosfolipidosi pulmonarja.